evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

185 questions · 194 findings · 16 reviews · Urology

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 40 · 20.6%GRADE not reported 15 · 7.7%Very low 29 · 14.9%Low 71 · 36.6%Moderate 35 · 18%High 4 · 2.1%

Sorafenib vs pazopanib (targeted agent versus targeted agent)

Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

Sorafenib probably leads to higher progression‐free survival (absolute effect size estimates based on… compared with pazopanib (targeted agent versus targeted agent) (moderate certainty).

1 finding from 1 review

Sorafenib vs pazopanib (targeted agent versus targeted agent)

Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

Sorafenib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with pazopanib (targeted agent versus targeted agent) (low certainty).

1 finding from 1 review

Sorafenib vs pazopanib (targeted agent versus targeted agent)

Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

It is very uncertain whether sorafenib changes serious adverse events (Grade 3 or 4) compared with pazopanib (targeted agent versus targeted agent) (very low certainty).

1 finding from 1 review

Sunitinib vs everolimus (targeted agent versus targeted agent)

Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

Sunitinib probably leads to lower progression‐free survival (absolute effect size estimates based on… compared with everolimus (targeted agent versus targeted agent) (moderate certainty).

1 finding from 1 review

Sunitinib vs everolimus (targeted agent versus targeted agent)

Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

Sunitinib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with everolimus (targeted agent versus targeted agent) (low certainty).

1 finding from 1 review

Sorafenib vs sunitinib (targeted agent versus targeted agent)

Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

It is very uncertain whether sorafenib changes overall survival (absolute effect size estimates based on survival… compared with sunitinib (targeted agent versus targeted agent) (very low certainty).

1 finding from 1 review

Sunitinib vs avelumab + axitinib (targeted agent versus immunotherapy + targeted agent)

Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

Sunitinib probably leads to higher progression‐free survival(absolute effect size estimates based on… compared with avelumab + axitinib (targeted agent versus immunotherapy + targeted… (moderate certainty).

1 finding from 1 review

Sunitinib vs avelumab + axitinib (targeted agent versus immunotherapy + targeted agent)

Overall survival (absolute effect size estimates based on survival rate at 12 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

Sunitinib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with avelumab + axitinib (targeted agent versus immunotherapy + targeted… (low certainty).

1 finding from 1 review

Sunitinib vs avelumab + axitinib (targeted agent versus immunotherapy + targeted agent)

Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

Sunitinib showed no clear difference in serious adverse events (Grade 3 or 4) compared with avelumab + axitinib (targeted agent versus immunotherapy + targeted… (low certainty).

1 finding from 1 review

Sunitinib vs pembrolizumab + axitinib (targeted agent versus immunotherapy + targeted agent)

Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

Sunitinib probably leads to higher progression‐free survival(absolute effect size estimates based on… compared with pembrolizumab + axitinib (targeted agent versus immunotherapy +… (moderate certainty).

1 finding from 1 review

Sunitinib vs pembrolizumab + axitinib (targeted agent versus immunotherapy + targeted agent)

Overall survival (absolute effect size estimates based on survival rate at 12 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

Sunitinib probably leads to higher overall survival (absolute effect size estimates based on survival… compared with pembrolizumab + axitinib (targeted agent versus immunotherapy +… (moderate certainty).

1 finding from 1 review

Sunitinib vs pembrolizumab + axitinib (targeted agent versus immunotherapy + targeted agent)

Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

Sunitinib showed no clear difference in serious adverse events (Grade 3 or 4) compared with pembrolizumab + axitinib (targeted agent versus immunotherapy +… (low certainty).

1 finding from 1 review

Sunitinib vs atezolizumab + bevacizumab (targeted agent versus immunotherapy + targeted agent)

Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

Sunitinib may leads to higher progression‐free survival(absolute effect size estimates based on… compared with atezolizumab + bevacizumab (targeted agent versus immunotherapy +… (low certainty).

1 finding from 1 review

Sorafenib vs sunitinib (targeted agent versus targeted agent)

Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

It is very uncertain whether sorafenib changes serious adverse events (Grade 3 or 4) compared with sunitinib (targeted agent versus targeted agent) (very low certainty).

1 finding from 1 review